Matrix-M with RH5.2 VLP and/or R21 for malaria, falciparum

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 3 May 2022: Trial registered, NCT05357560
  2. 10 Jul 2023: Trial started, NCT05357560

The trials

NCT05357560: A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21

State
Completed
Phase
Phase 1
People
107 taking part
Started
10 Jul 2023
Primary completion
11 Dec 2025
Arms
Group 1 - Infants R21 delayed 3rd dose, Group 2 - Infants R21 standard regimen, Group 3 - Adults RH5.2 low dose, standard regimen, Group 4 - Adults RH5.2 high dose, standard regimen, Group 5 - Adults RH5.2 and R21 low dose, standard regimen, Group 6 - Infants RH5.2 standard regimen, Group 7 - Infants RH5.2, delayed 3rd dose, Group 8 - Infants RH5.2 and R21, standard regimen, Group 9 - Infants RH5.2 and R21, delayed 3rd dose
Results
None posted
  1. 3 May 2022: Trial registered
  2. 10 Jul 2023: Trial started
  3. 11 Dec 2025: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.